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Background: A moderate low-carbohydrate diet has been receiving attention in the dietary management of
type 2 diabetes (T2DM). A fundamental issue has still to be addressed; how much carbohydrate delta-reduction
(Δcarbohydrate) from baseline would be necessary to achieve a certain decrease in hemoglobin A1c (HbA1c) levels.
Objective: We investigated the effects of three-graded stratification of carbohydrate restriction by patient baseline
HbA1c levels on glycemic control and effects of Δcarbohydrate on decreases in HbA1c levels (ΔHbA1c) in each group.
Research design and methods: We treated 122 outpatients with T2DM by three-graded carbohydrate restriction
according to baseline HbA1c levels (≤ 7.4% for Group 1, 7.5%-8.9% for Group 2 and≥ 9.0% for Group 3) and assessed
their HbA1c levels, doses of anti-diabetic drugs and macronutrient intakes over 6 months.
Results: At baseline, the mean HbA1c level and carbohydrate intake were 6.9 ± 0.4% and 252 ± 59 g/day for Group 1
(n = 55), 8.1 ± 0.4% and 282 ± 85 g/day for Group 2 (n = 41) and 10.6 ± 1.4% and 309 ± 88 g/day for Group 3 (n = 26).
Following three-graded carbohydrate restriction for 6 months significantly decreased mean carbohydrate intake (g/day)
and HbA1c levels for all patients, from 274 ± 78 to 168 ± 52 g and from 8.1 ± 1.6 to 7.1 ± 0.9% (n = 122, P < 0.001 for
both) and anti-diabetic drugs could be tapered. ΔHbA1c and Δcarbohydrate were −0.4 ± 0.4% and −74 ± 69 g/day for
Group 1, −0.6 ± 0.9% and −117 ± 78 g/day for Group 2 and −3.1 ± 1.4% and −156 ± 74 g/day for Group 3. Linear
regression analysis showed that the greater the carbohydrate intake, the greater the HbA1c levels at baseline
(P = 0.001). Also, the greater the reduction in carbohydrate intake (g/day), the greater the decrease in HbA1c levels
(P < 0.001), but ΔHbA1c was not significantly influenced by changes in other macronutrient intakes (g/day).
Conclusions: Three-graded stratification of carbohydrate restriction according to baseline HbA1c levels may
provide T2DM patients with optimal objectives for carbohydrate restriction and prevent restriction from being
unnecessarily strict.
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A low-carbohydrate diet (LCD) is defined as strict carbohy-
drate restriction to less than 130 g/day or less than 30%
carbohydrate [1,2]. LCDs have beneficial effects on glycemic
control, weight loss and serum lipid profiles compared to
high-carbohydrate low-fat (energy-restricted) diets [2-4].
Although long-term safety has not been proved by inter-
ventional studies, no serious harm has resulted from fol-
lowing LCDs for several years [2,5-7].
A moderate LCD is defined as modest carbohydrate
restriction to more than 130 g/day or 30 - 45% carbohy-
drate [1,2]. Moderate LCDs may be sufficiently effective
for glycemic control in Japanese patients with type 2 dia-
betes because the proportion of energy obtained from
carbohydrates or fat in East Asian populations, including
Japanese, is quite different from that in Western popula-
tions: higher carbohydrate (about 55 - 60%) and lower fat
percentages (about 20 - 25%) in Japanese population [8],
versus lower carbohydrate and higher fat percentages in
American population [9]. Accordingly, we modified the
LCD to suit Japanese patients with type 2 diabetes. The
moderate LCD we have used has been shown to be effect-
ive in reducing hemoglobin A1c (HbA1c) levels in Japanese
diabetic patients with lower to higher HbA1c levels with-
out reinforcement with anti-diabetic drugs [6,10-12]. The
principle of the moderate LCD in our previous studies
was two-graded stratification of carbohydrate restriction
according to the patient’s baseline HbA1c level (2-graded
moderate LCD) [6,10,11]. Patients with HbA1c levels <
9.0% were instructed to follow a 40 - 45% carbohydrate
diet, while those with HbA1c levels ≥ 9.0% were instructed
to follow a 30 - 33% carbohydrate diet; the former patients
achieved a HbA1c reduction of 0.7% in 1–2 years [6,11],
while the latter achieved a remarkable reduction of 3.1 -
3.6% in 6–12 months [10,11].
With the above 2-graded moderate LCD, however, both
type 2 diabetic patients with lower HbA1c levels and pa-
tients with moderate type 2 diabetes were included in one
group and both were required to follow a 40 - 45% carbo-
hydrate diet, though less aggressive carbohydrate restric-
tion might have been effective enough for the patients
with lower HbA1c levels. We believe that three-graded
stratification (3-graded moderate LCD) is more applicable
to patients with a wide range of baseline HbA1c levels, es-
pecially those with lower HbA1c levels.
There is another fundamental issue to consider in
achieving proper control of type 2 diabetes with any type
of LCD. In many previous LCDs, absolute goals for
carbohydrate intake, such as 150 g/day, were pre-set be-
fore starting them [3,6,10-17], which ignored patients’
own baseline carbohydrate intakes. We believe that
delta-reduction of carbohydrate can make the outcome
more predictable than absolute values. In this study,
therefore, we set a goal in terms of carbohydrate delta-reduction from baseline intake rather than an absolute
goal.
Thus, we designed this study to investigate the effects
of a 3-graded moderate LCD based on patient baseline
HbA1c levels (3 levels as opposed to 2 previously) on
glycemic control and also the effects of Δcarbohydrate
(g/day) rather than absolute volume on ΔHbA1c in each
group.
Patients and methods
Between April 2010 and December 2011, we recruited all
new outpatients with type 2 diabetes of Haimoto Clinic
with HbA1c levels of 6.5% or above for this study. We ex-
cluded patients with serum creatinine levels greater than
2.0 mg/dl (176.8 μmol/l), ketoacidosis, soft drink ketosis
[18], cancer or liver cirrhosis. Patients being treated with
insulin were also excluded because combination therapy
consisting of a moderate LCD and insulin has not been in-
vestigated. We also excluded patients who were following
carbohydrate restriction at baseline based on commercial
diet therapies, e.g. Atkins diet.
Of 138 eligible Japanese outpatients, 8 declined to partici-
pate, 6 were voluntarily lost to follow-up and 2 moved, and
thus 122 patients (72 men and 50 women; age: mean ± SD:
60 ± 9 years, range: 34–77 years) were investigated. After
obtaining written informed consent, patients were followed
up for 6 months.
The main protocol for the present study was approved
by the Ethical Committee of the Nagoya Tokushukai
General Hospital (approval number: 2010-2-104) and it
was also registered in University Hospital Medical Network
(UMIN000003425) before its start. The analysis re-
garding an association between Δintake of carbohy-
drate and ΔHbA1c levels was also approved by the Ethical
Committee.
Carbohydrate-reduced diet
The main principle of our moderate LCD is to eliminate
carbohydrate-rich food once or twice daily, at breakfast
and/or dinner [6,10-12]. We have instructed patients to
avoid carbohydrate-rich food in accordance with a list as
reported previously [6]. For the present research, based
on the results of our previous studies, we added a less
strict carbohydrate restriction category for the type 2 dia-
betic patients with lower HbA1c levels so patients were di-
vided into 3 groups according to their baseline HbA1c: ≤
7.4% (Group 1), 7.5% - 8.9% (Group 2) and ≥ 9.0% (Group
3). Patients with HbA1c levels ≤ 7.4% were instructed to
restrict carbohydrate-rich food to half of the usual amount
at dinner, those with 7.5% - 8.9% were instructed to elim-
inate it at dinner and those with levels ≥ 9.0% to elimin-
ate it at both dinner and breakfast. Patients were not
required to calculate daily carbohydrate intakes. While pa-
tients were forbidden to consume carbohydrate-containing
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protein and fat as they wished, including saturated fats.
There were no other restrictions.
An experienced dietician (Tae Sasakabe) performed all
the dietary assessments and gave instructions to all the
participants. The patients had not followed LCDs before
the present intervention. At baseline and after 6 months,
patients’ dietary intakes were assessed based on 3-day
dietary records. They were requested to maintain their
usual level of physical activity throughout the study.
Clinical assessment
We measured the body mass index (BMI), blood pres-
sure (BP) and HbA1c level of each patient every month.
Venous blood samples were obtained after an overnight
(12-h) fast at baseline and 6 months for the determination
of fasting plasma glucose (FPG), fasting serum insulin
(IRI), triglyceride, LDL cholesterol, HDL cholesterol and
creatinine levels.
We also recorded the doses of lipid-lowering or anti-
diabetic drugs (glibenclamide, gliclazide, glimepiride, nate-
glinide, metformin, pioglitazone, voglibose, sitagliptin) taken
by the patients.
Laboratory methods
The HbA1c levels were measured by high-performance
liquid chromatography (Arkley Co., Kyoto, Japan) and
estimated as National Glycohemoglobin Standardization
Program (NGSP) values (%) calculated by the formula
HbA1c (%) = HbA1c (Japan Diabetes Society, JDS) (%) ×
1.02 + 0.25 [19].
Plasma glucose concentrations were determined using
enzymatic methods (Shino-Test Co., Kanagawa, Japan).
Serum insulin levels were measured using the standard
double antibody radioimmunoassay method (Fujirebio
Inc., Tokyo, Japan). Enzymatic methods were used to meas-
ure serum creatinine and triglyceride concentrations (Daiichi
Pure Chemicals Co., Tokyo, Japan). Direct methods were
used to assay serum LDL cholesterol and HDL cholesterol
levels (Daiichi Pure Chemicals Co., Tokyo, Japan).
Statistical analysis
The parameter change for each biomarker (Δ) was defined
as the level after 6 months minus the level at baseline.
The Wilcoxon test was used to assess the changes in
HbA1c levels and other cardiovascular risk factors, total
energy and macronutrient intakes due to our moderate
LCD, and compare the levels between baseline and after
6 months for all patients. We computed Spearman’s
correlation coefficients (rs) to examine correlations be-
tween Δcabohydrate (g/day), Δ%carbohydrate (propor-
tion of energy from carbohydrate in total energy intake)
or Δother macronutrients and ΔHbA1c. Multiple regres-
sion analyses were performed to examine associationsbetween Δcabohydrate (g/day) or Δ%carbohydrate and
ΔHbA1c with adjustment for changes in energy intake
(Δtotal energy intake).
Increasing or decreasing trends in characteristics with
increasing baseline HbA1c levels were tested by linear
regression models including a score of 1, 2 and 3 given
to Group1, Group 2 and Group 3, respectively. Total en-
ergy intake was adjusted using the regression model. We
indicated changes in clinical (body mass index), bio-
logical (HbA1c, FPG, IRI and serum lipid profiles) and
nutritional [total energy intake and macronutrient intake
(g/day and %energy)] variables separately for each of the
3 groups. Then, increasing or decreasing trends in these
changes with increasing baseline HbA1c levels were tested
by linear regression models including the scores men-
tioned above. The total energy intake or Δtotal energy in-
take was adjusted using linear regression.
In addition, increasing or decreasing trends in ΔHbA1c
with increasing Δtotal energy intake were tested by linear
regression models including a score of 1, 2 and 3 given
to Δtotal energy Group 1, 2 and 3 stratified by tertile
of Δtotal energy intake, respectively. Furthermore, pa-
tients with > 80% decreases in total energy intake due to
reductions in carbohydrate intake were defined as carbo-
hydrate reduction predominant patients and others as
carbohydrate reduction less predominant patients. In each
group, we compared Δtotal energy and ΔHbA1c between
carbohydrate reduction predominant and less predomin-
ant patients using the t-test or Mann–Whitney test as
appropriate.
P-values less than 0.05 were considered statistically
significant. Data are shown as mean ± SD. All statistical
analyses were performed using SPSS (version 15.0; SPSS,
Inc., Chicago, IL, USA).
Results
Baseline characteristics of patients according to their
baseline HbA1c levels
The baseline characteristics of the 122 patients including
clinical and biological parameters are shown in Table 1.
The mean HbA1c level was 8.1 ± 1.6% (range: 6.5 -
14.1%). The mean levels were 6.9 ± 0.4% for Group 1,
8.1 ± 0.4% for Group 2 and 10.6 ± 1.4% for Group 3.
Correlations of HbA1c levels with macronutrients at
baseline
Baseline HbA1c levels were positively correlated with
baseline carbohydrate intake (g/day) (Figure 1A) and posi-
tively, though weakly, with total energy intake (rs = 0.292,
P = 0.001), but not with baseline %carbohydrate (rs =
0.152, P = 0.095). The correlation of baseline HbA1c levels
with baseline carbohydrate intake (g/day) remained signifi-
cant even after adjustment for total energy intake in linear
regression analysis (P = 0.015). Baseline HbA1c levels were
Table 1 Baseline characteristics of patients according to baseline HbA1c levels, and changes in HbA1c levels and
cardiovascular risk factors during 6 months (n = 122)
All patients Baseline hemoglobin A1c (%)*
Group 1 ≤ 7.4% Group 2
7.5 - 8.9%
Group 3 ≥ 9.0% P for trend Energy-adjusted
P for trend
n = 122 n = 55 n = 41 n = 26
Baseline
Male/female (n) 72/50 30/25 27/14 15/11
Age (years) 60.4 ± 9.3 62.2 ± 7.7 60.2 ± 10.1 56.6 ± 10.1 0.011 0.033
Duration of diabetes (months) 47 ± 66 32.1 ± 57.6 66.9 ± 75.2 47.8 ± 62.1 0.139 0.044
Hemoglobin A1c (%) 8.1 ± 1.6 6.9 ± 0.4 8.1 ± 0.4 10.6 ± 1.4 < 0.001 < 0.001
Fasting plasma glucose (mmol/l) 8.10 ± 2.39 6.66 ± 0.61 8.27 ± 1.66 10.8 ± 3.1 < 0.001 < 0.001
Fasting serum insulin (pmol/l) 44.3 ± 25.9 44.5 ± 26.9 44.6 ± 25.9 43.8 ± 24.4 0.918 0.583
Body mass index 24.8 ± 3.9 23.9 ± 3.8 25.6 ± 4.3 25.3 ± 2.8 0.061 0.205
Serum triglyceride (mmol/l) 1.50 ± 1.18 1.39 ± 1.02 1.72 ± 1.57 1.40 ± 0.62 0.721 0.886
Serum HDL-cholesterol (mmol/l) 1.45 ± 0.39 1.50 ± 0.39 1.37 ± 0.39 1.47 ± 0.31 0.653 0.877
Serum LDL-cholesterol (mmol/l) 3.39 ± 0.85 3.31 ± 0.83 3.36 ± 0.91 3.65 ± 0.80 0.112 0.073
Changes during 6 months P†
Δhemoglobin A1c (%)* −1.0 ± 1.4 < 0.001 −0.4 ± 0.4 −0.6 ± 0.9 −3.1 ± 1.4 < 0.001 < 0.001
Δfasting plasma glucose (mmol/l) −0.83 ± 1.94 < 0.001 −0.33 ± 1.05 −0.33 ± 1.89 −2.89 ± 2.16 < 0.001 < 0.001
Δserum insulin (pmol/l) −4.08 ± 19.2 0.010 4.92 ± 21.8 −6.06 ± 15.7 1.14 ± 16.5 0.05 0.220
Δbody mass index −0.86 ± 1.20 < 0.001 −0.81 ± 1.14 −0.91 ± 1.26 −0.86 ± 1.29 0.803 0.978
Δserum triglyceride (mmol/l) −0.18 ± 0.95 0.020 −0.06 ± 0.77 −0.31 ± 1.28 −0.21 ± 0.67 0.365 0.331
Δserum HDL-cholesterol (mmol/l) 0.10 ± 0.26 < 0.001 0.05 ± 0.28 0.10 ± 0.23 0.18 ± 0.23 0.022 0.024
Δserum LDL-cholesterol (mmol/l) −0.18 ± 0.85 0.004 −0.08 ± 0.80 −0.18 ± 0.83 −0.39 ± 1.01 0.156 0.309
Data are shown as mean ± SD. The participants were divided into three groups according to baseline hemoglobin A1c.
*Hemoglobin A1c (mmol/mol) = 10.93 × National Glycohemoglobin Standardization Program (%) - 23.52. P†: Wilcoxon test between baseline and after 6 months in
all patients.
rs = 0.354, P < 0.001
rs = 0.354, P < 0.001A B
Figure 1 Correlation of baseline HbA1c levels with baseline carbohydrate intake and that of Δcarbohydrate intake with baseline
carbohydrate intake. Green triangles indicate patients with HbA1c levels of ≤ 7.4%, blue squares those with HbA1c levels of 7.5% - 8.9%
and red circles those with HbA1c levels of ≥ 9.0%. Baseline HbA1c levels were positively correlated with baseline carbohydrate intake
(g/day) (A). Δcarbohydrate intake (g/day) was inversely and very strongly correlated with baseline carbohydrate intake (g/day) with consumption
of the moderate LCDs (B).
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centage in total energy intake (%fat) and protein intake, but
there was a weak, inverse correlation with baseline protein
percentage in total energy intake (%protein) (rs = −0.250,
P = 0.004).
We observed significant increasing trends in total en-
ergy and carbohydrate intakes (g/day) and a decreasing
trend in %protein with an increasing trend in baseline
HbA1c levels, but this trend in baseline carbohydrate in-
take (g/day) was no longer significant after adjustment
for total energy intake (Table 2). No significant trend
was found for %carbohydrate or other indices of macro-
nutrients with increasing baseline HbA1c levels.
Changes in macronutrients during 6 months
The daily carbohydrate intake ranged widely at baseline,
from 140 g to 579 g. The average carbohydrate intake
(g/day) significantly decreased, from 274 ± 78 g (54 ± 8%
of total energy) at baseline to 168 ± 52 g (41 ± 11%) after
6 months (Table 2). The total energy intake also signifi-
cantly decreased. There was a slight increase in fat intake
but it was significant. While there was no change in pro-
tein intake over 6 months, %protein significantly increased
due to a marked decline in total energy intake.
At the end of the study, intakes of total energy and
carbohydrate were 1591 ± 361 kcal/day and 178 ± 54 g/dayTable 2 Baseline intakes of total energy and macronutrients a
hemoglobin A1c levels (n = 122)
Energy and nutrients All patients
Group 1 ≤ 7.4
n = 122 n = 55
Baseline
Total energy intake (kcal/day) 2047 ± 549 1914 ± 381
Carbohydrate intake (g/day) 274 ± 78 252 ± 59
%carbohydrate (%) 54.0 ± 8.2 52.9 ± 7.8
Fat intake (g/day) 58 ± 20 57.2 ± 17.9
%fat (%) 25.4 ± 6.1 26.8 ± 6.6
Protein intake (g/day) 77 ± 22 75.0 ± 19.1
%protein (%) 15.3 ± 2.7 15.8 ± 2.6
Changes during 6 months P†
Δtotal energy intake (kcal day) −399 ± 508 < 0.001 −323 ± 430
Δcarbohydrate intake (g/day) −106 ± 80 < 0.001 −74 ± 69
Δ%carbohydrate (%) −12.5 ± 10.0 < 0.001 −8.0 ± 9.2
Δfat intake (g/day) 6 ± 27 0.041 0.7 ± 24.6
Δ%fat (%) 9.1 ± 9.3 < 0.001 5.5 ± 8.9
Δprotein intake (g/day) −0.4 ± 22.8 0.938 −1.5 ± 20.8
Δ%protein (%) 3.6 ± 3.8 < 0.001 2.9 ± 3.4
Data are shown as mean ± SD. The participants were divided into 3 groups accordin
biomarker (Δ) was defined as the level after 6 months minus the level at baseline.
Standardization Program (%) - 23.52. P†: Wilcoxon test between baseline and after(44.8 ± 9.9%) for Group 1, 1710 ± 424 kcal/day and 165 ±
44 g/day (39.9 ± 10.8%) for Group 2 and 1666 ± 455 kcal/
day and 153 ± 54 g/day (37.1 ± 10.2%) for Group 3. Intakes
of fat and protein were 58 ± 22 g/day (32.2 ± 7.7%) and
74 ± 18 g/day (18.7 ± 3.1%) for Group 1, 70 ± 30 g/day
(36.1 ± 9.3%) and 80 ± 24 g/day (19.4 ± 3.3%) for Group 2
and 67 ± 20 g/day (36.8 ± 8.1%) and 80 ± 24 g/day (19.4 ±
3.3%) for Group 3, respectively.
Δcarbohydrate (g/day) was inversely and very strongly
correlated with baseline carbohydrate intake (g/day)
(Figure 1B), while Δ%carbohydrate was inversely and weakly
correlated with baseline %carbohydrate (rs = −0.226,
P = 0.012) as a result of following our moderate LCD
for 6 months.
Changes in HbA1c levels and other cardiovascular risk
factors during 6 months in all patients
Compared to baseline, the mean HbA1c and FPG levels
significantly decreased over 6 months, from 8.1 ± 1.6 to
7.1 ± 0.9% and 8.10 ± 2.39 to 7.21 ± 1.55 mmol/l (P <
0.001 for both). The mean IRI levels and BMI also sig-
nificantly decreased, from 44.3 ± 25.9 to 40.3 ± 25.8
pmol/l and 24.8 ± 3.9 to 23.9 ± 3.7 (P = 0.010 for IRI and
P < 0.001 for BMI) (Table 1).
Serum lipid profiles, including serum triglyceride, HDL-
cholesterol and LDL-cholesterol, significantly improved innd their changes during 6 months by baseline
Baseline hemoglobin A1c (%)*
% Group 2
7.5 - 8.9%
Group 3 ≥ 9.0% P for trend Energy-adjusted
P for trend
n = 41 n = 26
2048 ± 595 2323 ± 678 0.002
282 ± 85 309 ± 88 0.001 0.209
55.6 ± 8.3 54.1 ± 9.0 0.349 0.088
53.7 ± 19.4 65.1 ± 23.2 0.206 0.177
23.5 ± 5.1 25.3 ± 5.9 0.130 0.126
77.8 ± 21.6 80.7 ± 26.8 0.259 0.073
15.5 ± 3.0 13.9 ± 2.1 0.007 0.047
−338 ± 500 −657 ± 601 0.012
−117 ± 78 −156 ± 74 < 0.001 < 0.001
−15.6 ± 8.5 −16.9 ± 10.4 < 0.001 < 0.001
16.3 ± 27.9 2.0 ± 24.5 0.394 0.002
12.6 ± 9.0 11.4 ± 8.1 0.001 0.051
1.3 ± 20.9 −1.0 ± 29.8 0.826 0.011
3.3 ± 3.9 5.4 ± 3.8 0.009 0.036
g to baseline hemoglobin A1c levels. The parameter change for each
*Hemoglobin A1c (mmol/mol) = 10.93 × National Glycohemoglobin
6 months in all patients.
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6 months (Table 1). After 39 patients taking lipid-lowering
drugs were excluded (n = 83), there were still significant
improvements in serum HDL-cholesterol (P < 0.001) and
LDL-cholesterol (P = 0.021). While there was also a de-
crease in serum triglyceride, it was not statistically signifi-
cant (P = 0.120).
Correlation of changes in HbA1c levels with those in
carbohydrate intake during 6 months in all patients
ΔHbA1c was positively correlated with Δcarbohydrate in-
take (g/day) (rs = 0.457, P < 0.001) (Figure 2A), Δ%carbo-
hydrate (rs = 0.248, P = 0.006) (Figure 2B) and Δtotal
energy intake (rs = 0.306, P = 0.001). However, focusing on
the results for each group, the correlation of ΔHbA1c with
Δcarbohydrate intake (g/day) was weaker in Group 1 (rs =
0.281, P = 0.038), but stronger in Group 2 (rs = 0.376, P =
0.015) and Group 3 (rs = 0.349, P = 0.081).
ΔHbA1c was weakly and negatively correlated with Δ%
protein (rs = −0.253, P = 0.005). ΔHbA1c was not sig-
nificantly correlated with Δprotein (g/day) (rs = 0.086,
P = 0.345), Δfat (g/day) (rs = 0.038, P = 0.675) or Δ%fat
(rs = −0.157, P = 0.084).
In multiple regression analyses with adjustment for Δtotal
energy intake, the correlations of Δcarbohydrate (g/day)
or Δ%carbohydrate with ΔHbA1c remained significant
(P = 0.002 for Δcarbohydrate [g/day] and P < 0.001 for
Δ%carbohydrate). In contrast, the significant correlation
of Δtotal energy intake with ΔHbA1c disappeared with
adjustment for Δcarbohydrate (g/day) (P = 0.945), while ars = 0.457, P < 0.001
A
Figure 2 Correlations of ΔHbA1c with Δcarbohydrate. Green triangles
HbA1c levels of 7.5% - 8.9% and red circles those with HbA1c levels of≥ 9.
(g/day) (A) and Δ%carbohydrate (B). Focusing on individual Groups, the corre
(rs = 0.281, P = 0.038), while stronger in Group 2 (rs = 0.376, P = 0.015) and Grcorrelation remained with adjustment for Δ%carbohydrate
(P < 0.001).
Correlations of changes in HbA1c levels with those in BMI
or serum lipid profiles during 6 months in all patients
We found no correlation between ΔHbA1c and ΔBMI
(rs = 0.167, P = 0.065) (Figure 3A), Δserum LDL-cholesterol
(rs = 0.031, P= 0.734) (Figure 3B) or Δserum triglyceride (rs =
0.126, P = 0.166, Figure 3C), while there was a negative
and weak correlation between ΔHbA1c and Δserum HDL-
cholesterol (rs = −0.211, P = 0.020) (Figure 3D).
Changes in HbA1c levels, cardiovascular risk factors and
macronutrients across 3 groups
ΔHbA1c and Δcarbohydrate were −0.4 ± 0.4% and −74 ±
69 g/day for Group 1 (n = 55), −0.6 ± 0.9% and −117 ± 78 g/
day for Group 2 (n = 41) and −3.1 ± 1.4% and −156 ± 74 g/
day for Group 3 (n = 26), respectively (Tables 1 and 2). De-
creasing trends in ΔHbA1c, ΔFPG, Δcarbohydrate intake
and Δtotal energy intake were evident across the 3 groups.
Regarding other macronutrients, significant increasing
trends in Δ%fat and Δ%protein were also evident, but
such trends for Δfat (g/day) and Δprotein (g/day) were
not significant across the 3 groups. After adjustment
for Δtotal energy intake, the trends remained materially
the same except for those in Δfat intake and Δprotein
intake, for which there was a significant increase after
adjustment.
We found no correlations for changes in other cardiovas-
cular risk factors, including Δbody mass index, ΔIRI, Δserumrs = 0.248, P = 0.006B
indicate patients with HbA1c levels of≤ 7.4%, blue squares those with
0%. For all patients, ΔHbA1c was positively correlated with Δcarbohydrate
lation of ΔHbA1c with Δcarbohydrate (g/day) was weaker in Group 1
oup 3 (rs = 0.349, P = 0.081).
rs = 0.126, P = 0.166
rs = 0.031, P = 0.734
rs = -0.211, P = 0.020
rs = 0.167, P = 0.065A
C D
B
Figure 3 Correlations of changes in HbA1c levels with those in BMI and serum lipid profiles during 6 months in all patients. Green
triangles indicate patients with HbA1c levels of≤ 7.4%, blue squares those with HbA1c levels of 7.5% - 8.9% and red circles those with HbA1c
levels of≥ 9.0%. We found no correlation between ΔHbA1c and ΔBMI (A), Δserum LDL-cholesterol (B) or Δserum triglyceride (C), while there
was a negative and weak correlation between ΔHbA1c and Δserum HDL-cholesterol (D).
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groups, though an increasing trend in Δserum HDL-
cholesterol was significant (Table 1). After adjustment for
Δtotal energy intake, the significant trend remained. After
excluding 39 patients who received lipid-lowering drugs,
however, the trend in Δserum HDL-cholesterol across the
3 groups lost significance (P = 0.184).
In addition, trends in ΔHbA1c with increasing baseline
IRI levels were tested by linear regression models includ-
ing a score of 1, 2 and 3 given to tertile of baseline IRI
levels: IRI-Group 1 (mean IRI level: 20.2 ± 5.22 pmol/l),
IRI-Group 2 (38.9 ± 5.46 pmol/l) and IRI-Group 3 (74.4 ±
20.4 pmol/l), respectively. ΔHbA1c values were −0.8 ±
1.3% for IRI-Group 1, −1.3 ± 1.5% for IRI-Group 2
and −0.9 ± 1.4% for IRI-Group 3. We found no variation
in ΔHbA1c across the three IRI Groups (P = 0.651).Comparison of ΔHA1c between carbohydrate reduction
predominant and less predominant patients by tertile of
Δtotal energy intake
We analyzed data to examine whether the effect of Δcar-
bohydrate intake on ΔHbA1c was independent of Δtotal
energy intake by comparison of ΔHb1c between carbo-
hydrate reduction predominant and less predominant
patients stratified by tertile of Δtotal energy intake
(Δtotal energy Groups 1–3). The results are shown in Table 3
and Figure 4. The mean reduction in total energy intake
was not significantly different between the carbohydrate
reduction predominant patients and the carbohydrate re-
duction less predominant patients in the three Δtotal en-
ergy Groups. The decrease in HbA1c levels was greater in
the patients with the highest reductions in carbohydrate
intake than in those with lower reductions in each Δtotal
Table 3 Comparison of ΔHA1c between carbohydrate reduction predominant and less predominant patients: stratified









Δtotal energy Group 1 (n = 41) −939 ± 422
Carbohydrate reduction predominant patients (n = 16) −866 ± 325 0.557 −817 ± 264 −11 ± 140 −1.6 ± 1.5 0.185‡
Carbohydrate reduction less predominant patients (n = 25) −984 ± 476 −591 ± 325 −165 ± 154 −1.3 ± 1.6
Δtotal energy Group 2 (n = 41) −347 ± 106
Carbohydrate reduction predominant patients (n = 28) −331 ± 104 0.178 −455 ± 211 113 ± 231 −1.4 ± 1.7 0.008§
Carbohydrate reduction less predominant patients (n = 13) −380 ± 108 −214 ± 96 −82 ± 72 −0.3 ± 0.6
Δtotal energy Group 3 (n = 40) 99 ± 208
Carbohydrate reduction predominant patients (n = 37) 101 ± 216 0.980 −241 ± 184 256 ± 191 −0.6 ± 0.9 0.258‡
Carbohydrate reduction less predominant patients (n = 3) 74 ± 54 193 ± 104 −142 ± 44 −0.1 ± 0.6
Data are shown as mean ± SD. P*: Mann–Whitney test between carbohydrate reduction predominant patients and less predominant patients.
†: Hemoglobin A1c (mmol/mol) = 10.93 × National Glycohemoglobin Standardization Program (%) - 23.52. ‡: Mann–Whitney test, §: t-test.
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significant in Δtotal energy Group 2 (P = 0.008).
Changes in anti-diabetic drugs
At baseline, 36 of the 122 patients (30%) had already
been prescribed anti-diabetic drugs by other physicians
(Table 4). At the end of the study, the number of pa-
tients taking anti-diabetic drugs had decreased to 17
(14%), half of the baseline number. In 25 patients, medi-
cation was eliminated or reduced in the study periodFigure 4 Comparison of ΔHA1c between carbohydrate
reduction predominant and less predominant patients in three
Groups stratified by tertile of Δtotal energy intake. Purple
circles indicate Δtotal energy Group 1, gray circles Δtotal energy
Group 2 and cobalt blue circles Δtotal energy Group 3. The mean
decrease in HbA1c levels was greater in the patients with the
highest reductions in carbohydrate intake (closed circles) than in
those with lower reductions (open circles) in each Δtotal energy
Group. The difference was statistically significant in Δtotal
energy Group 2 (p = 0.008).while in 12, it was increased or newly started. The re-
duction in carbohydrate intake was greater in the former
(−132 ± 86 g/day) than in the latter (−122 ± 86 g/day),
but the difference did not reach statistical significance
(P = 0.095) (Figure 5).
Twenty-five (61%) of the 41 patients in Group 2 were
taking anti-diabetic drugs at baseline, but the number of
patients on anti-diabetic drugs decreased from 25 to 12
during the 6 months, a more remarkable reduction than
in the other 2 groups.
Discussion
In the current study on Japanese patients with type 2 dia-
betes, a 3-graded moderate LCD with patients assigned to
each grade according to baseline HbA1c (≤7.4%, 7.5% -
8.9% and ≥ 9.0%) led to remarkable reductions in both
carbohydrate and total energy intakes. In spite of not hav-
ing restrictions on total energy intake or fat intake, fat
intake did not increase enough to compensate for the re-
markable reduction in carbohydrate intake in this study.
The remarkable decrease in total energy intake during
6 months, therefore, was almost certainly due to a great
reduction in carbohydrate intake, not a reduction in fat
intake. Under such circumstances, Δcarbohydrate (g/day)
was correlated with ΔHbA1c independently of Δtotal en-
ergy intake [20].
Based on the results for the above nutritional changes,
the 3-graded moderate LCD achieved good glycemic
control - HbA1c levels of around 7.0% after 6 months
in all groups despite the variation in baseline HbA1c
levels - without reinforcement by anti-diabetic drugs.
The patients with lower HbA1c levels were assigned to
Group 1 under the 3-graded moderate LCD and their
carbohydrate intake was restricted the least severely.
A −74 g-carbohydrate restriction in this group pro-
duced a −0.4% reduction in HbA1c after 6 months. If
Table 4 Anti-diabetic drugs at baseline and after 6 months by baseline hemoglobin A1c levels (n = 122)
All patients Baseline hemoglobin A1c (%)*
Group 1 ≤ 7.4% Group 2 7.5 – 8.9% Group 3 ≥ 9.0%
n = 122 n = 55 n = 41 n = 26
Baseline (n) 36 (30%) 6 (11%) 25 (61%) 5 (19%)
Glibenclamide 4 (3.45 mg) 0 3 (3.8 mg) 1 (2.5 mg)
Gliclazide 1 (120 mg) 0 1 (120 mg) 0
Glimepiride 22 (1.84 mg) 3 (1.5 mg) 15 (2.0 mg) 4 (1.5 mg)
Nateglinide 3 (120 mg) 0 3 (120 mg) 0
Metformin 12 (521 mg) 3 (417 mg) 8 (531 mg) 1 (750 mg)
Pioglitazone 9 (23 mg) 4 (23 mg) 2 (30 mg) 3 (20 mg)
Voglibose 16 (0.6 mg) 4 (0.7 mg) 10 (0.6 mg) 2 (0.9 mg)
Sitagliptin 8 (56 mg) 0 7 (57 mg) 1 (50 mg)
After 6 months (n) 17 (14%) 1 (2%) 12 (29%) 4 (15%)
Glibenclamide 2 (4.4 mg) 0 1 (7.5 mg) 1 (1.25 mg)
Gliclazide 1 (120 mg) 0 1 (120 mg) 0
Glimepiride 12 (1.4 mg) 1 (1.0 mg) 9 (1.6 mg) 2 (0.8 mg)
Nateglinide 0 0 0 0
Metformin 10 (600 mg) 0 7 (571 mg) 3 (667 mg)
Pioglitazone 1 (30 mg) 0 1 (30 mg) 0
Voglibose 5 (0.5 mg) 0 5 (0.5 mg) 0
Sitagliptin 4 (63 mg) 0 4 (63 mg) 0
The percentages indicate the proportion of patients that were prescribed each drug. Values in parentheses are the mean daily dose per person for anti-diabetic

























Figure 5 Changes in carbohydrate intake (g/day) between
patients with less medication and those with more medication
over 6 months. In 25 patients (blue lines), medication was eliminated
or reduced in the study period while in 12 (orange lines), it was
increased or newly started. The mean reduction in carbohydrate
intake was greater in the former than in the latter, but the
difference did not reach statistical significance (P = 0.095).
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Group 1 would have been subjected to a −117 g-carbohy-
drate restriction. Thus, the carbohydrate restriction was
lightened by 43 g in the patients with lower HbA1c levels.
These results suggest that the 3-graded moderate LCD
was effective for patients with lower HbA1c levels and
avoided an unnecessarily strict carbohydrate restriction
on them.
The diet was not as effective in patients in Group 2 as
in the other groups. Reducing carbohydrate by 117 g de-
creased HbA1c by 0.6%. The effect of Δcarbohydrate on
ΔHbA1c was smaller than expected. We assume one of
the reasons to be that patients received less and less anti-
diabetic drugs, especially sulfonylureas, in the course of
the study because of concern about hypoglycemia. Thus,
the effect of the 3-graded moderate LCD in Group 2 was
actually better than it appeared from the results.
Awareness of hypoglycemia has recently increased
because it is associated with a significant increase in
macrovascular events, mortality and dementia [21,22] and
hypoglycemia is a major adverse effect of anti-diabetic
drugs, chiefly sulfonylureas [21]. Some patients did not re-
strict their carbohydrate intake as we instructed, while
other patients over-restricted it. Therefore, the tapering of
sulfonylurea doses in patients with lower HbA1c levels is
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of the moderate-LCD, we tapered the dose of sulfonyl-
ureas to about half of baseline to prevent hypoglycemia
and monitored blood glucose levels every one or two
weeks. Careful attention to dietary compliance and blood
glucose levels is therefore necessary during the period
from 1 to 2 months after beginning the moderate LCD.
We compared our results with two epoch-making
studies reported by Westman et al. [14] and Gannon
et al. [23]. First of all, American patients with type 2 dia-
betes had a lower carbohydrate intake (245 g/day) and
greater BMI (30–38) than our Japanese subjects [14]. Re-
garding baseline HbA1c levels, Westman’s patients
(mean HbA1c level: 8.3%) were close to our patients in
Group 2 while Gannon’s patients (mean HA1c level:
10.0%) were close to our patients in Group 3. Westman’s
patients achieved a 1.5% decrease in a HbA1c level cor-
responding to a 196 g/day reduction in carbohydrate in-
take, while the decrease in our Group 2 was much less.
In view of this result, greater carbohydrate restriction
should have been imposed on the patients in Group 2 in
order to achieve a HbA1c level < 7.0% with tapering of
anti-diabetic drugs. In contrast, a 30% carbohydrate diet
(Δ%carbohydrate: −15%) led to a 2.5% reduction in HbA1c
level in Gannon’s patients, while a 37% carbohydrate diet
(Δ%carbohydrate: −17%) led to a 3.1% reduction in HbA1c
levels in our patients in Group 3. This indicates that the
3-graded moderate LCD was sufficiently effective in our
patients with a higher HbA1c level.
The 3-graded moderate LCD achieved similarly good
results in patients in all groups. At the end of the study,
daily carbohydrate intake and HbA1c levels were 153 g
and 7.5% in Group 3, 165 g/day and 7.5% in Group 2
and 178 g and 6.4% in Group 1, respectively. The results
were relatively close to each other in spite of the great
difference in HbA1c levels and carbohydrate intakes at
baseline, which ranged from 6.5 to 14.1% and 140 to
579 g/day at baseline, respectively. While patients with
higher baseline HbA1c levels had been consuming larger
amounts of carbohydrate, our moderate LCD regimen
decreased carbohydrate intake to a greater extent in
such patients. This suggests that we could adopt the diet
for any baseline HbA1c level or amount of carbohydrate
intake and achieve equally good results with respect to
targets.
Deterioration of glycemic control in patients with higher
HbA1c levels can be due to lower endogenous insulin se-
cretion and/or poor dietary compliance. In the current
study, ΔHbA1c was not associated with baseline IRI levels,
though it was clearly correlated with Δcarbohydrate. Thus,
a higher carbohydrate intake due to poor dietary com-
pliance seems to be a more important as a cause of de-
terioration of glycemic control than endogeneous insulin
secretion. However, this needs to be studied furtherbecause a correlation between Δinsulin secretion and
Δcarbohydrate intake has still to be addressed.
Although it is ideal to calculate precise baseline carbo-
hydrate intakes (g/day) based on dietary records and give
patients individual targets for delta-reductions in carbo-
hydrate intake from baseline, in our experience doing
this is too time consuming. Our results indicated the
amount of carbohydrate reduction necessary to achieve
a certain decrease in HbA1c levels in each group. They
will allow us to give clear and accurate goals for carbo-
hydrate delta-reduction from baseline to individual pa-
tients. However, considering that it is not easy to assess
quantities of carbohydrate intake at baseline, it would be
more practical to start instruction by telling patients to
eliminate carbohydrate-rich food once or twice daily, at
breakfast and/or dinner, according to baseline HbA1c
levels, without assessing carbohydrate intakes. If a patient
could not achieve an individual optimal target HbA1c
level after 3–6 months, we would modify the quantity of
daily carbohydrate intake based on the current findings.
To aid the instruction of patients in this regard, a list of
foods giving their carbohydrate contents (e.g. 60 g carbo-
hydrate in a bowl of rice and 30 g carbohydrate in a slice
of bread) would be accurate enough. Despite the difficulty,
accurate assessment of carbohydrate consumption at
baseline and during the course of the dietary treatment
would give patients more consistent carbohydrate and en-
ergy deficits.
Several reviews on LCDs have mentioned the 2 different
ways of expressing carbohydrate restriction (i.e., g/day
and %) [1,2]. The current study demonstrates that
baseline HbA1c levels were correlated with carbohy-
drate intake (g/day) but not with %carbohydrate. Also,
Δcarbohydrate (g/day) was very strongly (inversely) corre-
lated with baseline carbohydrate intake (g/day), but weakly
with Δ%carbohydrate, and ΔHbA1c was strongly corre-
lated with Δcarbohydrate (g/day), but weakly with
Δ%carbohydrate. Furthermore, g/day is more intuition-
ally acceptable to patients than% carbohydrate when
instructing them. This suggests that expression of carbo-
hydrate intake in g/day is superior to expressing it as %
carbohydrate for the management of patients with type 2
diabetes given moderate LCDs.
The first limitation of our study is that the results
could be partly due to changes in exercise amounts and
medications. Indeed, the number of patients on anti-
diabetic drugs decreased in the study period, especially
in Group 2. Further studies on patients not taking anti-
diabetic drugs will be required to resolve this issue. The
second limitation is that we did not directly compare
3-graded moderate LCD with 2-graded moderate LCD. A
direct comparison will be required to determine whether
more detailed stratification of carbohydrate restriction by
levels of baseline HbA1c can allow patients with lower
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of carbohydrate intake and still achieve sufficient gly-
cemic control. The third limitation is that though the
stricter carbohydrate restriction imposed on patients with
HbA1c ≥ 9% achieved a considerable decrease in HbA1c
levels, a similar result might have been achieved with less
strict carbohydrate restriction. A study design in which
patients are randomly assigned to 3-graded stratification
(i.e., regardless of patient’s baseline HbA1c level) might
provide useful findings in this regard. Although better
glycemic control was achieved by a greater reduction in
carbohydrate intake in this study, the long-term safety of
LCDs has not been proved by interventional studies. In
view of this, we believe it important to know the minimal
carbohydrate restriction that is effective for glycemic con-
trol as well as the maximal carbohydrate restriction that is
feasible for patients. At the same time, we should not hesi-
tate to impose stricter carbohydrate restriction on patients
when necessary.
In conclusion, the 3-graded stratification of carbohydrate
restriction depending on patients’ baseline HbA1c levels
achieved HbA1c levels of around 7.0% after 6 months des-
pite great differences in baseline HbA1c levels and carbo-
hydrate intake. We found that the greater the reduction in
carbohydrate intake (g/day), the greater the decrease in
HbA1c levels. We also demonstrated that the amount of
carbohydrate reduction necessary to achieve a certain
HbA1c decrease in each group. Our dietary strategy may
provide patients with type 2 diabetes with optimal and
practical objectives for carbohydrate restriction and pre-
vent restriction from being unnecessarily strict.
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